Rapid Micro Biosystems, Inc. (NASDAQ: RPID)

Rapid Micro Biosystems, Inc. is a life sciences technology company that specializes in providing automated microbial quality control (MQC) solutions for pharmaceutical manufacturing. The company operates in the bioprocessing and pharmaceutical quality control industry, focusing on the efficient and safe production of healthcare products such as biologics, cell and gene therapies, vaccines, and sterile injectables. Rapid Micro Biosystems is leading a global transformation toward fully automated MQC, enabling faster, safer, and higher capacity drug production through its innovative technology.

The company generates revenue primarily through the sale of its flagship Growth Direct platform, which includes the Growth Direct system, proprietary consumables, lab information management system (LIMS) connection software, and comprehensive customer support and validation services. The Growth Direct platform automates and modernizes traditional MQC testing workflows, replacing manual processes with advanced robotic automation, optical imaging, and algorithmic vision analysis. This platform is designed to deliver faster results, greater accuracy, increased operational efficiency, and better compliance with data integrity regulations. The company's customer base includes top pharmaceutical companies and manufacturers of FDA-approved cell and gene therapies, indicating a strong position in the high-growth biologics and cell and gene therapy markets.

• Growth Direct Platform: The Growth Direct platform is the company's core offering, comprising the Growth Direct system, proprietary consumables, LIMS connection software, and comprehensive customer support and validation services. This platform automates and digitizes the MQC process, enabling pharmaceutical manufacturers to perform critical testing more efficiently, accurately, and securely. The Growth Direct system is a fully automated, high-throughput system for processing MQC samples, designed to absorb the vast majority of daily MQC test volume in any pharmaceutical manufacturing facility. The platform's proprietary consumables include plates for environmental monitoring, water testing, in-process bioburden, and sterility release applications, all custom-designed for automated handling and image processing within the Growth Direct system. The LIMS connection software allows for two-way integration with a customer's LIMS, enabling a fully paperless workflow and seamless data transfer. The company also offers additional software such as the Mold Alarm software, which adds features or expands capabilities. The platform is supported by comprehensive validation services, including Installation Qualification, Operational Qualification, Performance Qualification, Time-To-Results Qualification, 21 CFR Part 11 Assessment, and Method Qualification/Method Suitability. The company provides full 24/7 maintenance support via annual service contracts, ensuring high reliability and customer satisfaction.

Rapid Micro Biosystems holds a strong position within the pharmaceutical quality control industry, particularly in the automated MQC sector. The company's competitive advantages include its proprietary technology platform, which offers best-in-class automated and secure MQC testing. The Growth Direct platform is purpose-built to meet the growing demands of global pharmaceutical manufacturing, providing superior detection and enumeration capabilities, increased accuracy through automation, and robust security and connectivity. The company's investment in patent-protected innovation across multiple technology disciplines, including systems design, robotic handling, microbiology, optical imaging, software image analysis, data management and security, and process automation, further strengthens its competitive position. Rapid Micro Biosystems has cultivated long-standing and collaborative relationships with top-tier customers, establishing the Growth Direct platform as an industry standard globally. The company's deep integration into heavily regulated pharmaceutical manufacturing processes and its highly attractive business model, which leverages a growing installed base of systems to generate persistent recurring revenues through consumables and service contracts, are additional competitive strengths.

The company's customer base includes 75% of the top twenty largest pharmaceutical companies as measured by revenue and the manufacturers of a number of FDA-approved cell and gene therapies, including 86% of approved gene-modified autologous CAR-T cell therapies. Rapid Micro Biosystems has placed 190 systems and sold approximately 9 million consumables globally, with customers across approximately 107 sites in 18 countries. The majority of customers have multiple Growth Direct systems, and over 40% have deployed the systems across multiple facility locations. This broad adoption underscores the company's strong market presence and the value of its automated MQC solutions in the pharmaceutical industry.